Treatment of Metabolic Syndrome and Obesity

Categories: Other Disorders

Reference #: 2022-019

OTC Contact: Tracy Bruehs, M.S., J.D., Associate Director for Licensing and Contracts, (202) 687-7629 (Directory Information | Send a Message)

Contracts Guide

Disclose Your Invention
MTA/CDA Assistance
COVID-19 Related Agreements
Main Campus Research
Office of Sponsored Research
Education Links

Connect with Industry

Technologies for Licensing
Industry Collaboration Opportunities
Research and Clinical Trials


Georgetown University researchers discovered a potential drug treatment that inhibits the activity of a neutral amino acid transporter in fat cells, preventing the development of adipocyte exuberance, resulting in weight loss and reduced adipocyte hypertrophy in mice under a chronic high fat diet. This innovation reveals potential methods and compositions for treating obesity or reducing weight or fat mass in a subject.


Adipocytes, or fat cells, serve as a sink for lipid storage in our bodies. However, when lipid accumulation far exceeds their breakdown, adipocytes, in response, will enlarge, expand, and ultimately recruit immune cells to adipose tissues and promote inflammation. There are no effective drugs to prevent this pathological metabolic response, “adipocyte exuberance,” which can lead to obesity and chronic health problems if not regulated. Therefore, strategies to temper adipocyte exuberance might restore adipocyte homeostasis and prevent the development of obesity and associated diseases.



Stage of Development

To confirm the pharmacological study, researchers are currently examining the effect of the genetic deletion of a specific amino acid transporter, specifically in adipocytes in mice under a high-fat diet.

Patent Status

Provisional application has been filed.


Jeffrey Huang, PhD

Mi-Hye Lee, PhD